Dendritic Cell Therapy in Germany: Options, Solutions and Cost

We organize Dendritic Cell Vaccination in Germany
Surgical Experts works with a leading clinic in Germany for dendritic cell therapy, a form of cancer immunotherapy that uses your own immune cells to fight cancer.
Dendritic cells play a key role in the immune system. They present antigens to T cells and start an immune response against pathogens or abnormal cells, such as cancer cells.
In dendritic cell vaccination, therefore, these cells are collected from your blood, prepared in the laboratory to strengthen their ability to activate the immune system, and given back to you as a vaccine to help your immune system target cancer cells.
Dendritic cell therapy at a glance
- What it is: a personalized cancer vaccine made from your own immune cells
- Who it may help: patients with various solid tumors, usually in addition to standard treatment
- Timeline: blood draw on day 1, ICD therapy during preparation, dendritic cell vaccination on day 8
- Stay in Germany: at least 8 days for the first treatment cycle
- Number of vaccinations: usually 2-4, depending on your treatment plan
- Cost: from around €58,000, depending on your personal plan
- Your first step: send us your medical reports for a free review
You only book after a personal Zoom consultation with the treating doctor. Until then, there is no commitment and no cost.
What is Dendritic Cell Therapy?
Dendritic cells are a type of immune cell found in tissues that are in contact with the outside world, such as the skin and the linings of the nose, lungs, stomach and intestines. They are also present in an immature form in the blood. These cells are essential for the immune system, because they act as messengers between the innate and the adaptive immune system.
Dendritic cells capture antigens from pathogens or cancer cells and present them on their surface. This presentation activates T cells, a type of white blood cell that plays a central role in the body’s immune response.
In cancer treatment, this ability is used in a targeted way. In a dendritic cell vaccine, dendritic cells are obtained from the patient, loaded with tumor antigens in the laboratory and then given back to the patient. The prepared dendritic cells can train T cells to recognize and attack cancer cells.
In addition, dendritic cell vaccines can be combined with other forms of immunotherapy, such as checkpoint inhibitors, to strengthen the immune response against the tumor. Because of their central role in immune activation, dendritic cells are an important focus of modern cancer research.

Preparing the immune system: immunogenic cell death (ICD) with Newcastle Disease Virus
Many tumors are very good at hiding from the immune system. Doctors often call them “cold” tumors: the immune system is present, but it does not recognize the cancer cells as dangerous. A dendritic cell vaccine can only work well if the immune system can see the tumor clearly. For this reason, our partner clinic prepares the immune system before vaccination with a treatment that triggers immunogenic cell death.
What is immunogenic cell death (ICD)?
Every day, cells in our body die in a quiet, controlled way that the immune system ignores. Immunogenic cell death is different. Here, tumor cells die in a way that sends out clear alarm signals to the immune system.
When a cancer cell dies through ICD, three important things happen:
- “Eat me” signal: a protein called calreticulin appears on the surface of the dying cancer cell. It tells immune cells: “Take me up and examine me.”
- “Find me” signal: the cell releases ATP, a molecule that attracts dendritic cells to the tumor.
- “Danger” signal: the protein HMGB1 is released and activates dendritic cells, so they become fully alert.
At the same time, the dying tumor cells release their tumor antigens, the unique features of your cancer. In other words, ICD turns the tumor into a “wanted poster” that the immune system can read.
How does Newcastle Disease Virus (NDV) trigger ICD?
Newcastle Disease Virus is a bird virus that does not cause disease in humans. It prefers to multiply in cancer cells, because many tumor cells have lost their natural antiviral defense. Healthy cells, on the other hand, can usually protect themselves from the virus.
When NDV infects cancer cells, it can trigger immunogenic cell death. In addition, the virus leaves viral proteins on the surface of the tumor cells and stimulates the release of interferons, the body’s own alarm messengers. Together, these signals help turn a “cold” tumor into a “hot” one that the immune system can recognize.
Why ICD before the dendritic cell vaccine?
Dendritic cells are the “trainers” of the immune system. To train T cells to attack cancer, they need two things: the tumor antigens (what to attack) and strong danger signals (that it is urgent). Without danger signals, the immune system may even learn to tolerate the tumor instead of fighting it.
ICD provides both. As a result, the dendritic cell vaccine meets an immune system that is already alert, and the T cells it activates find a tumor that is easier to recognize. This is why our partner clinic combines both steps in one treatment concept:
- ICD therapy with NDV: the tumor is made visible and the immune system is alerted.
- Dendritic cell vaccine: your own dendritic cells are loaded with tumor antigens in the laboratory and train the T cells to attack the cancer.
- Additional therapies if needed: depending on your findings, the doctor may add other treatments, for example to keep the activated T cells from being “switched off” by the tumor.
Is NDV therapy safe? What does research show?
NDV has been studied in cancer patients for several decades. In studies, it was generally well tolerated. The most common side effects are mild flu-like symptoms such as fever, chills and tiredness, which usually pass within one to two days.
However, NDV is not an approved standard cancer treatment. The research consists mainly of laboratory studies and smaller clinical studies, and larger controlled trials are still missing. The treating doctor will explain the current evidence, the possible benefits and the risks for your individual situation during your Zoom consultation.
Does Dendritic Cell Vaccination work for cancer treatment?
Clinical studies have shown encouraging results with dendritic cell vaccination in several types of cancer, including melanoma, prostate cancer, breast cancer, pancreatic cancer, glioblastoma and brain stem tumors.
In some patients, especially those whose cancer did not respond to conventional treatment, studies have reported tumor shrinkage or longer survival. However, results vary widely between patients and cancer types, and not every patient responds.
Dendritic cell vaccination is often combined with other treatments, such as other immunotherapies, chemotherapy or radiation therapy. Combining treatments may help overcome the limits of each single therapy. Whether a combination makes sense in your case is decided by the treating doctor after reviewing your medical reports.
Is cancer immunotherapy with dendritic cells safe?
Dendritic cell therapy is generally considered safe, and side effects are usually mild and short-lived. Common side effects include flu-like symptoms such as fever, chills, tiredness and muscle aches. Occasionally, patients have a reaction at the injection site or a mild allergic reaction.
Serious side effects are rare but can include severe allergic or autoimmune reactions. Overall, the safety profile of dendritic cell vaccination is considered favorable, especially compared with chemotherapy or radiation therapy. As with any medical treatment, the treating doctor discusses the possible risks and benefits with you before you decide.
Is dendritic cell vaccination (DCV) FDA approved?
One cell-based cancer vaccine in this group is approved: sipuleucel-T (Provenge), an immunotherapy made from the patient’s own antigen-presenting cells. The U.S. FDA approved it in 2010 for certain patients with advanced prostate cancer. In the European Union it is no longer authorized.
However, most other dendritic cell vaccines do not have FDA or EU marketing approval. They are produced individually for each patient and are being studied in clinical trials for cancers such as melanoma, glioblastoma, prostate and colorectal cancer.
In Germany, individually produced dendritic cell vaccines are offered by specialized clinics under the applicable German regulations for individually manufactured cell therapies. During your consultation, the treating doctor will explain the legal basis, the approval status and what this means for you.
Who can benefit from dendritic cell vaccines?
For most types of cancer, there are standard treatments that have been developed and tested over decades. We therefore recommend using these treatments and, where appropriate, supplementing them with immunotherapy. Research suggests that tumor cells damaged by chemotherapy or radiation may be easier for the immune system to recognize.
Dendritic cell therapy in Germany is also used when conventional treatments have not been successful. Patients with the following cancers have been treated with dendritic cell vaccines:
- Prostate cancer
- Pancreatic cancer
- Lung cancer
- Colon cancer
- Ovarian cancer
- Breast cancer
- Kidney cancer (renal cell carcinoma)
- Glioblastoma
- Brain stem tumors
- Malignant melanoma
In general, the immune system tends to work more effectively when the tumor burden is low. For this reason, dendritic cell therapy is often considered alongside standard treatment, not only as a last option. Whether you are a suitable candidate, and when treatment would make most sense, can only be decided by the doctor after reviewing your medical reports.
Who is not a suitable candidate?
Dendritic cell therapy is not the right choice for every patient. An honest assessment is important to us, because it protects you from treatment that is unlikely to help.
Treatment may not be possible or may need special review if you:
- Have an active autoimmune disease
- Take high-dose cortisone or other drugs that suppress the immune system
- Are in a very weak general condition – Kanofky score !
- Have a severe active infection]]
- Have received an organ transplant – needs to be proofed
In addition, every case is different. The treating doctor reviews your medical reports and tells you openly whether dendritic cell therapy makes sense for you, or whether another treatment would be better.
How does dendritic cell therapy work? Step by step
Patients from abroad often ask how the treatment is organized and how long they need to stay in Germany. The process has two parts: the preparation from home and the treatment in the clinic.
Before your trip
- Send your medical reports. Our medical team and the treating doctor review your documents.
- Zoom consultation with the doctor. You discuss your situation, the treatment options and realistic expectations.
- Personal treatment plan and cost estimate. You receive a written plan with a transparent cost breakdown.
- Travel preparation. We send you a medical invitation letter for your visa and help you with flights and accommodation.
Your treatment in Germany
Day 1 – Intake and blood draw
The doctor welcomes you to the clinic, examines you and goes through your treatment plan with you once more. After that, blood is drawn. From this blood, the laboratory obtains the immune cells that later become your dendritic cells.
ICD therapy with Newcastle Disease Virus
While your vaccine is being prepared, you receive ICD therapy with Newcastle Disease Virus. It makes the tumor cells visible to the immune system and puts your immune system on alert, so it is ready for the vaccine.
In the laboratory – your dendritic cells are prepared
At the same time, your immune cells are developed into dendritic cells in the laboratory. Next, they are loaded with tumor antigens, the features of the tumor that your immune system should learn to recognize. In this way, every vaccine is made individually for you.
Day 8 – Dendritic cell vaccination
About eight days after the blood draw, you receive your personal dendritic cell vaccine. The dendritic cells now “train” your T cells to recognize and attack the cancer cells.
After the vaccination – follow-up
You receive a medical report in English for your oncologist at home. The doctor also explains which follow-up examinations are recommended and whether further vaccinations are planned.
As a result, you should plan a stay of at least eight days in Germany for the first treatment cycle. The exact schedule is part of your personal treatment plan and is explained during the Zoom consultation.
How much does Immunotherapy in Germany cost?
Cancer immunotherapy with dendritic cells starts at around €58,000. Programs that combine dendritic cell vaccination with other immunotherapies can cost up to around €155,000.
However, the final cost depends on your personal treatment plan. A single vaccination is usually not enough to build a lasting immune response, so treatment plans typically include several vaccinations. Depending on your findings, the doctor may recommend combining them with other therapies, such as checkpoint inhibitors or oncolytic virus therapy.
In some cases, hyperthermia (controlled heating of the tumor area) is added. Heat may make tumor cells more sensitive to other treatments and more visible to the immune system. Whether hyperthermia is useful for you is decided by the doctor.
For this reason, to give you an honest and accurate cost estimate, we first need your medical reports. After the doctor has reviewed them, you will receive a personal treatment plan with a transparent cost breakdown.
Dendritic Cell-based Cancer Vaccine
Dendritic cell vaccine, a form of cancer immunotherapy, has shown promise in treating certain types of cancer. However, quantifying its success rate can be challenging due to variations in patient populations, cancer types, and treatment protocols across clinical trials and medical centers.
Studies have reported varying success rates, with some patients experiencing significant tumor regression or prolonged periods of disease stabilization. For example, in clinical trials for metastatic melanoma, dendritic cell vaccination has demonstrated objective response rates ranging from 10% to 20%, with durable responses observed in a subset of patients.
Success rates may also depend on factors such as the patient’s immune system health, tumor characteristics, and concurrent treatments. Additionally, dendritic cell therapy is often used combined with other immunotherapies or conventional treatments, which can influence outcomes.
Clinical Trials of Dendritic Cell Vaccination
Here are a few important and relevant clinical trials involving dendritic cell vaccination that have been completed:
- Dendritic Cell-Based Immunotherapy for Prostate Cancer 202
- Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
- Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy
- Effectivity of long antigen exposition dendritic cell vaccination in the palliative treatment of pancreatic cancer
- Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
- Research progress on dendritic cell vaccine in cancer immunotherapy Dendritic Cells Vaccination in Cancer Immunotherapy Clinical Trials: Are We Making Progress?
- Dendritic cells and immunity against cancer
- Additional long antigen exposition dendritic cell vaccination in the Palliative Treatment of Stage IV Colorectal Cancer Patients
- A Dendritic Cell Vaccination Was Safe and Immune Responses in Patients With Multiple Myeloma
- Final results of brain cancer glioblastoma clinical trial
- Dendritic Cell Vaccination of Glioblastoma: Road to success or death end
- Research on dendritic cell therapy for AML (acute myeloid leukemia) has shown promising results
- Antitumour dendritic cell vaccination in a priming and boosting approach
Conclusion:
Dendritic Cell Vaccination holds significant promise as a novel approach to cancer treatment. Ongoing research efforts aim to further elucidate its mechanisms of action, optimize treatment protocols, and expand its applicability across different types of cancer.

Your first step to a new tomorrow
We organize your dendritic cell vaccination and immunotherapy in Germany
You only book after a personal Zoom consultation with the treating doctor, so you can ask all your questions before making any decision.
Surgical Experts selects its clinical partners very carefully. For this reason, you are treated by specialists with more than 20 years of experience in dendritic cell therapy.
Our medical concierge service takes care of the organization for you, from your first contact to your return home. Your offer includes:
- On-site medical concierge support during your stay
- Transfers from the airport to your hotel or clinic and back
- Help with appointments, documents and communication with the clinic
As a next step, find out whether you are a candidate for dendritic cell vaccination. Send us your medical reports, and our team will get back to you.